The conversation delves into the complex relationship between big pharma and public trust, particularly regarding vaccines. While acknowledging the historical misdeeds of pharmaceutical companies, the discussion highlights that vaccines often serve as a loss leader, generating minimal revenue compared to other drugs. This nuanced perspective challenges the common perception of greed in the vaccine market, suggesting that the financial incentives may not align as one might expect.
